

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 213542000101

Application Number 09/991,548


Applicant

Lennart OLSSON and Tatjana NARANDA

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

RECEIVED
AUG 07 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
MD	1.	01/31/1995	5,385,888	Goodenow et al.			
MD	2.	06/17/1997	5,639,458	Olsson et al.			
MD	3.	12/08/1998	5,846,827	Celis et al.			
MD	4.	12/29/1998	5,853,999	Olsson et al.			
MD	5.	03/23/1999	5,885,574	Elliot			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
MD	6.	07/26/1990	WO 90/08161	WIPO			
MD	7.	09/07/1990	WO 90/10016	WIPO			
MD	8.	11/14/1991	WO 91/17253	WIPO			
MD	9.	09/16/1993	WO 93/17699	WIPO			
MD	10.	02/23/1995	WO 95/05189	WIPO			
MD	11.	02/08/1996	WO 96/03438	WIPO			
MD	12.	05/23/1996	WO 96/15426	WIPO			
MD	13.	11/14/1996	WO 96/35443	WIPO			
MD	14.	09/12/1997	WO 97/32899	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
MD	15.	Ebina et al. (1985). "The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling," <i>Cell</i> 40:747-758.
MD	16.	EMBL accession number M38027, published by Fukunaga et al. (1990), visited on June 6, 2002. 1991
MD	17.	EMBL accession number M59820, published by Fukunaga et al. (1990), visited on June 6, 2002.
MD	18.	EMBL accession number X55720, published by Larsen et al. (1990), visited on June 6, 2002. 1991

EXAMINER

Marianne DeB...

DATE CONSIDERED:

4/28/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 213542000101

Application Number 09/991,444

Applicant

Lennart OLSSON and Tatjana NARANDA

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

RECEIVED
AUG 07 2002
TECH CENTER 1600/2900

19. EMBL accession number X55721, published by Larsen et al. (1990), visited on June 6, 2002.
20. Fukumoto et al. (1989). "Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues," *J. Biol. Chem.* 264(14):7776-7779.
21. GenBank Accession No. D28561, published by Kasahara et al. (1997), visited on June 10, 2002.
22. GenBank Accession No. M20747, published by Fukumoto et al. (1989), visited on June 10, 2002.
23. GenBank Accession No. A18657, published by ~~by WO 91/47253~~ 1994
24. GenBank Accession No. U43168, published by Tartaglia et al. (1995), visited on June 10, 2002.
25. GenBank Accession No. U32324, published by Van Leuvan (1996), visited on June 10, 2002.
26. GenBank Accession No. U31993, published by Yao et al. (1995), visited on June 10, 2002.
27. Gribskov and Burgess (1986). "Sigma factors from *E. Coli*, *B. subtilis*, phage SP01, and phage T4 are homologous proteins," *Nucl. Acids Res.* 14(16):6745-6763.
28. Haft et al. (1994). "Involvement of dileucine motifs in the internalization and degradation of the insulin receptor," *J. Biol. Chem.* 269(42):26286-26294.
29. Hamer (1997). "Dual role of a dileucine motif in insulin receptor endocytosis," *J. Biol. Chem.* 272(35):21685-21691.
30. Hansen et al. (1989). "Inhibition of insulin receptor phosphorylation by peptides derived from major histocompatibility complex class I antigens," *PNAS USA* 86:3123-3126.
31. Korpi and Seeburg (1993). "Natural mutation of GABA_A receptor alpha6 subunit alters benzodiazepine affinity but not allosteric GABA effects," *Eur. J. Pharm.* 247:23-17.
32. Larsen et al. (1990). "Expression cloning of human granulocyte colony-stimulating factor receptor: A structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains," *J. Exp. Med.* 172:1559-1570.
33. Leonard et al. (1984). "Molecular cloning and expression of cDNAs for the human interleukin-2 receptor," *Nature* 311:626-631.
34. Levy-Toledano et al. (1993). "Deletion of C-terminal 113 amino acids impairs processing and internalization of human insulin receptor: comparison of receptors expressed in CHO and NIH-3T3 cells," *Biochem. Biophys. Acta.* 1220:1-14.
35. Li et al. (1994). "An irregularity in the transmembrane domain helix correlates with the rate of insulin receptor internalization," 33(47):14333-14338.
36. Naranda et al. (1997). "A peptide derived from an extracellular domain selectively inhibits receptor internalization: target sequences on insulin and insulin-like growth factor 1 receptors," *PNAS USA* 11692-11697.
37. Naranda et al. (1999). "Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site," *PNAS USA* 96:7569-7974.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 213542000101

Application Number 09/991,548

Applicant

Lennart OLSSON and Tatjana NARANDA

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

RECEIVED
AUG 07 2002
TECH CENTER 16001a

38. Ngo et al. "The protein folding problem and tertiary structure prediction," Merz & LeGrand, Birkhauser Boston pp. 491-495. 1994
39. Olsson et al. (1994). "Regulation of receptor internalization by the major histocompatibility complex class I molecule," *PNAS USA* 91:9086-9090.
40. Piper et al. (1992). "The efficient intracellular sequestration of the insulin-regulatable glucose transported (GLUT-4) is conferred by the NH2 terminus," *J. Cell Biol.* 117(4):729-743.
41. Rajagopalan et al. (1995). "Chimeric receptors expressing juxtamembrane sequences of the insulin receptor undergo rapid endocytosis in the absence of receptor tyrosine kinase activity," *Biochem. Biophys. Res. Commun.* 211(3):714-718.
42. Rudinger (1976). "Characteristics of the amino acids as components of a peptide hormone sequence," *In Peptide Hormones* J. Parsons ed. University Park Press: Baltimore, MD pp. 1-7.
43. Salgaller et al. (1994). "Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide," *Canc. Immunol. Immunother.* 39:105-116.
44. Silver et al. (1992). "Atomic structure of a human MHC insulin molecule presenting an influenza virus peptide," *Nature* 360:367-369.
45. Stagsted et al. (1990). "Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen," *Cell* 62:297-307
46. Stagsted et al. (1991). "A preformed, ordered structure of a 25-residue peptide derived from a major histocompatibility complex class I antigen is required to affect insulin receptor function," *J. Biol. Chem.* 266(20):12844-12847.
47. Stagsted et al. (1993). "Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide," *J. Pharm. Exper. Therap.* 267(2):997-1001.
48. Stagsted et al. (1993). "Inhibition of internalization of glucose transporters and IGF II receptors," *J. Biol. Chem.* 268(30):22809-22813.
49. Staubs et al. (1994). "Localization of the insulin receptor binding sites for the SH2 domain proteins p85, Syp, and GAP," *J. Biol. Chem.* 269(44):27186-27192.
50. Strader et al. (1989). "Structural basis of beta-adrenergic receptor function," *FASEB J.* 3:1825-1832.
51. Swissprot accession number P00533, published by Ullrich et al. (1984), visited on 6/6/2002.
52. Swissprot accession number P08887, published by Yamasaki et al. (1998), visited on 6/6/2002. 1988
53. Swissprot accession number P19235, published by Ehrenman (1991), visited on 6/6/2002.
54. Swissprot accession number P24024, published by Tong et al. (1990), visited on 6/6/2002.
55. Swissprot accession number P25025, published by Murphy et al. (1991), visited on 6/6/2002.
56. Swissprot accession number P40238, published by Vigon et al. (1992), visited on 6/6/2002.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 213542000101	Application Number 09/221,548
	Applicant Lennart OLSSON and Tatjana NARANDA	
	Filing Date November 20, 2001	Group Art Unit 1644
	Mailing Date July 31, 2002	

- | | | |
|----|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MP | 57. | Swissprot accession number P42701, published by Chua et al. (1994), visited on 6/6/2002. |
| MP | 58. | Tartaglia et al. (1995). "Identification and expression cloning of leptin receptor, OB-R," <i>Cell</i> 83:1263-1271. |
| MP | 59. | Ullrich et al. (1984). "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene A431 epidermoid carcinoma cells," <i>Nature</i> 309:418-425. |
| MP | 60. | Verhey et al. (1995). "Distinct signals in the GLUT4 glucose transporter for internalization and for targeting to an insulin-responsive compartment," <i>J. Cell Biol.</i> 130(5):1071-1079. |
| MP | 61. | Verland et al. (1989). "Specific molecular interaction between the insulin receptor and a D product of MHC class I," <i>J. Immun.</i> 143(3):945-951. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.